cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2023-3382cardiovascular-3382Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESОстаточный риск у пациентов с атеросклеротическими кардиоваскулярными заболеваниямиResidual risk in patients with atherosclerotic cardiovascular diseasehttps://orcid.org/0000-0001-8050-2892ХазоваЕ. В.KhazovaE. V.

Елена Владимировна Хазова — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней им. профессора С. С. Зимницкого.

Казань

Kazan

hazova_elena@mail.ruhttps://orcid.org/0000-0002-7228-5848БулашоваО. В.BulashovaO. V.

Ольга Васильевна Булашова — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней им. профессора С. С. Зимницкого.

Казань

Kazan

boulashova@yandex.ruФГБОУ ВО Казанский государственный медицинский университет Минздрава РоссииKazan State Medical University20230601202322133823382Copyright © Хазова Е.В., Булашова О.В., 20232023Хазова Е.В., Булашова О.В.Khazova E.V., Bulashova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3382

Остаточный риск у пациентов с атеросклерозом, несмотря на спорные моменты его понимания, остается актуальной проблемой современной кардиологии. В статье представлен обзор публикаций по распространенности и значению для определения прогноза остаточного риска, который в настоящее время трактуется как риск макрои микрососудистых осложнений у пациентов с атеросклеротическими сердечно-сосудистыми заболеваниями (АССЗ), принимающих стандартную терапию, с достижением оптимальных уровней холестерина липопротеинов низкой плотности, артериального давления и глюкозы крови. Сделана попытка обоснования значения определения остаточного риска в стратегии вторичной профилактики сердечно-сосудистых событий в эпоху лечения пациентов с атеросклерозом статинами. Освещены современные взгляды на факторы, ассоциированные с возникновением остаточного воспалительного и липидного рисков у пациентов с АССЗ, в т.ч. при сочетании с хронической сердечной недостаточностью и сахарным диабетом, прогностическую значимость остаточного риска у таких больных.

The residual risk in patients with atherosclerosis, despite the its controversial aspects, remains an urgent problem of modern cardiology. The article presents a review of publications on the prevalence and significance for determining the prognosis of residual risk, which is currently interpreted as the risk of macroand microvascular complications in patients with atherosclerotic cardiovascular disease (ACVD) taking standard therapy, with the achievement of optimal levels of low-density lipoprotein cholesterol, blood pressure and glucose. Based on available publications, we highlighted current views on the factors associated with residual inflammatory and lipid risks in ACVD patients, including those associated with heart failure and diabetes, and the prognostic significance of residual risk in such patients. An attempt was made to rationale the significance of determining the residual risk for secondary prevention of cardiovascular events.

атеросклерозрезидуальный сердечно-сосудистый рискишемическая болезнь сердцахроническая сердечная недостаточностьatherosclerosisresidual cardiovascular riskcoronary artery diseaseheart failureReferencesОстроумова О. Д., Кочетков А. И., Листратов А.И. Комбинированная гиполипидемическая терапия с позиций современных рекомендаций по лечению дислипидемии. Медицинский алфавит. 2021;(17):13-9. doi:10.33667/2078-5631-2021-17-13-19.Ostroumova OD, Kochetkov AI, Listratov AI. Combined lipid-lowering therapy from standpoint of modern guidelines for management of dyslipidaemias. Medical alphabet. 2021;(17):13-9. (In Russ.) doi:10.33667/2078-5631-2021-17-13-19.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002.Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Journal of Atherosclerosis and Dyslipidemias 2020;1(38):7-42. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.Берштейн Л.Л. Новые возможности снижения резидуального риска при ишемической болезни сердца. Кардиология. 2020;60(11):110-6. doi:10.18087/cardio.2020.11.n1370.Bershtein LL. New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease. Kardiologiia. 2020;60(11):110-6. (In Russ.) doi:10.18087/cardio.2020.11.n1370.Гаврилова Н. Е., Метельская В. А., Яровая Е. Б. и др. Оценка липидного профиля при использовании липид-снижающей терапии (статинов) у лиц с коронарным атеросклерозом. Рациональная Фармакотерапия в Кардиологии. 2015;11(5):459-63. doi:10. 20996/1819-6446-2015-11-5-459-463.Gavrilova NE, Metelskaya VA, Yarovaya EB, et al. Assessment of lipid profile when using lipid-lowering therapy (statins) in patients with coronary atherosclerosis. Rational Pharmacotherapy in Cardiology. 2015;11(5):459-63. (In Russ.) doi:10. 20996/1819-6446-2015-11-5-459-463.Greene SJ, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circ Heart Fail. 2020;13(6):e007132. doi:10.1161/CIRCHEARTFAILURE.120.007132.Greene SJ, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circ Heart Fail. 2020;13(6):e007132. doi:10.1161/CIRCHEARTFAILURE.120.007132.Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;5;64(5): 485-94. doi:10.1016/j.jacc.2014.02.615.Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;5;64(5): 485-94. doi:10.1016/j.jacc.2014.02.615.Guedeney P, Claessen BE, Baber U, et al. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019;123(11):1788-95. doi:10.1016/j.amjcard.2019.03.005.Guedeney P, Claessen BE, Baber U, et al. Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019;123(11):1788-95. doi:10.1016/j.amjcard.2019.03.005.Ambrosy AP, Yang J, Sung SH, et al. Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc. 2021;10(20):e020377. doi:10.1161/JAHA.120.020377.Ambrosy AP, Yang J, Sung SH, et al. Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc. 2021;10(20):e020377. doi:10.1161/JAHA.120.020377.Sniderman A, Williams K, Contoins J, et al. A meta-analysis of low density lipoprotein cholesterol, non-density lipoprotein cholesterol and apolipoprotein B as a markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-45. doi:10.1161/CIRCOUTCOMES.110.959247.Sniderman A, Williams K, Contoins J, et al. A meta-analysis of low density lipoprotein cholesterol, non-density lipoprotein cholesterol and apolipoprotein B as a markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-45. doi:10.1161/CIRCOUTCOMES.110.959247.Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-802. doi:10.1016/j.jacc.2019.02.032.Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791-802. doi:10.1016/j.jacc.2019.02.032.Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017;40(3):138-48. doi:10.1002/clc.22692.Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017;40(3):138-48. doi:10.1002/clc.22692.Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26. doi:10.1186/1475-2840-13-26.Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26. doi:10.1186/1475-2840-13-26.Miettinen TA, Gylling H, Strandberg T, et al. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4 S Investigators. BMJ. 1998;316:1127-30. doi:10.1136/bmj.316.7138.1127.Miettinen TA, Gylling H, Strandberg T, et al. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4 S Investigators. BMJ. 1998;316:1127-30. doi:10.1136/bmj.316.7138.1127.Ridker PM. How Common Is Residual Inflammatory Risk? Circ Res. 2017;120(4):617-9. doi:10.1161/CIRCRESAHA.116.310527.Ridker PM. How Common Is Residual Inflammatory Risk? Circ Res. 2017;120(4):617-9. doi:10.1161/CIRCRESAHA.116.310527.Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018;138(2):131-40. doi:10.1161/CIRCULATIONAHA.118.034032.Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018;138(2):131-40. doi:10.1161/CIRCULATIONAHA.118.034032.Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of Interleukin-ip and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020;76(14):1660-70. doi:i0.i0i6/j.jacc.2020.08.0ii.Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of Interleukin-ip and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020;76(14):1660-70. doi:i0.i0i6/j.jacc.2020.08.0ii.Ridker PM. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J Am Coll Cardiol. 20i8;72(25):3320-3i. doi:i0.i0i6/j.jacc.20i8.06.082.Ridker PM. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J Am Coll Cardiol. 20i8;72(25):3320-3i. doi:i0.i0i6/j.jacc.20i8.06.082.Kraler S, Wenzl FA, Luscher TF. Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. Eur J Clin Invest. 2020;50(12):e13424. doi:10.1111/eci.13424.Kraler S, Wenzl FA, Luscher TF. Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. Eur J Clin Invest. 2020;50(12):e13424. doi:10.1111/eci.13424.Генкель В. В., Кузнецова А. С., Сумеркина В.А. и др. Увеличение уровня высокочувствительного С-реактивного белка как маркер мультифокального атеросклероза у пациентов с сердечно-сосудистыми заболеваниями. Медицинский совет. 2019;(16):86-93. doi:10.21518/2079-701X-2019-16-86-93.Genkel VV, Kuznetcova AS, Sumerkina VA, et al. Increase in high-sensitive C-reactive protein as a marker of polyvascular disease in patients with cardiovascular diseases. Medical Council. 2019;(16):86-93. (In Russ.) doi:10.21518/2079-701X-2019-16-86-93.Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-82. doi:10.1016/S0140-6736(09)60447-5.Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-82. doi:10.1016/S0140-6736(09)60447-5.Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. doi:10.2217/clp.10.84.Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9-20. doi:10.2217/clp.10.84.Zhao Y, Xiang P, Coll B, et al. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications. 2021;35(3):107767. doi:10.1016/j.jdiacomp.2020.107767.Zhao Y, Xiang P, Coll B, et al. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications. 2021;35(3):107767. doi:10.1016/j.jdiacomp.2020.107767.Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25. doi:10.1016/S0140-6736(08)60104-X.Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25. doi:10.1016/S0140-6736(08)60104-X.Bielecka-Dabrowa A, Bytyci I, Von Haehling S, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):188. doi:10.1186/s12944-019-1135-z.Bielecka-Dabrowa A, Bytyci I, Von Haehling S, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):188. doi:10.1186/s12944-019-1135-z.Davidson MH. Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020;31(2):108-10. doi:10.1097/MOL.0000000000000672.Davidson MH. Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020;31(2):108-10. doi:10.1097/MOL.0000000000000672.Зубарева М. Ю., Рожкова Т. А., Горнякова Н. Б. и др. Резидуальный (остаточный) риск у больных очень высокого риска с атерогенными дислипидемиями, находящихся на терапии статинами. Проспективное исследование "КРИСТАЛЛ" Часть 1: Цель, задачи, дизайн и исходные характеристики включенных пациентов. Атеросклероз и дислипидемии. 2013;1:26-34.Zubareva MYu, Rozhkova TA, Gornyakova NB, et al. Residual risk in patients treated with statins from the very high risk group of development atherogenic dyslipidemia. A prospective study "CRYSTAL" Part 1: Purpose, objectives, design, and baseline characteristics of the included patients. Ateroskleroz i dislipidemii. 2013;1:26-34. (In Russ.)Gitt AK, Lautsch D, Ferrieres J, et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in Brief. 2018;18:1937-40. doi:10.1016/j.dib.2018.04.092.27 Gitt AK, Lautsch D, Ferrieres J, et al. Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world. Data in Brief. 2018;18:1937-40. doi:10.1016/j.dib.2018.04.092.Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П. и др. (от имени исследователей DYSIS). Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11(4):70-8. doi:10.15829/1728-8800-2012-4-70-78.Oganov RG, Kukharchuk VV, Arutyunov GP, et al. (on behalf of the DYSIS Study Group). Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8. (In Russ.) doi:10.15829/1728-8800-2012-4-70-78.Берштейн Л. Л., Збышевская Е. В., Катамадзе Н. О. и др. ISCHEMIA — крупнейшее в истории рандомизированное исследование по стабильной ишемической болезни сердца. Исходные характеристики включенных пациентов на примере российского центра. Кардиология. 2017;57(10):12-9. doi:10.18087/cardio.2017.10.10038.Bershtein LL, Zbyshevskaya EV, Katamadze NO, et al. ISCHEMIA — the Largest Ever Randomized Study in Stable Coronary Artery Disease. Baseline Characteristics of Enrolled Patients in One Russian Site. Kardiologiia. 2017;57(10):12-9. (In Russ.) doi:10.18087/cardio.2017.10.10038.Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366.Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366.Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172-80. doi:10.1093/eurheartj/ehx566.Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172-80. doi:10.1093/eurheartj/ehx566.Munkhaugen J, Otterstad JE, Dammen T, et al. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Preventive Cardiology. 2018;25(9):923-31. doi:10.1177/2047487318768940.Munkhaugen J, Otterstad JE, Dammen T, et al. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Preventive Cardiology. 2018;25(9):923-31. doi:10.1177/2047487318768940.Kramer F, Voss S, Roessig L, et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1675-83. doi:10.1002/ejhf.1787.Kramer F, Voss S, Roessig L, et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1675-83. doi:10.1002/ejhf.1787.Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-9. doi:10.1161/01.cir.0000053730.47739.3c.Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-9. doi:10.1161/01.cir.0000053730.47739.3c.Zambon A. Холестерин, не связанный с липопротеинами высокой плотности, и сердечно-сосудистые заболевания у пациентов с сахарным диабетом и дислипидемией. Сахарный диабет. 2020;23(1):65-71. doi:10.14341/DM10351.Zambon A. Nonhigh-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia. Diabetes mellitus. 2020;23(1):65-71. (In Russ.) doi:10.14341/DM10351.Уткина Е. А., Афанасьева О. И., Покровский С. Н. Гетерогенность липопротеидов и их роль в развитии сердечно-сосудистых заболеваний. Российский кардиологический журнал. 2019;(5):82-9. doi:10.15829/1560-4071-2019-5-82-89.Utkina EA, Afanasieva OI, Pokrovsky SN. The heterogeneity of lipoproteins and their role in the development of cardiovascular diseases. Russian Journal of Cardiology. 2019;(5):82-9. (In Russ.) doi:10.15829/1560-4071-2019-5-82-89.Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941-50. doi:10.1016/S2213-8587(17)30313-3.Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941-50. doi:10.1016/S2213-8587(17)30313-3.Opotowsky AR, Valente AM, Alshawabkeh L, et al. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. Eur Heart J. 2018;39(34):3253-61. doi:10.1093/eurheartj/ehy362.Opotowsky AR, Valente AM, Alshawabkeh L, et al. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. Eur Heart J. 2018;39(34):3253-61. doi:10.1093/eurheartj/ehy362.

The authors declare that there are no conflicts of interest present.